The PubMed entry presents a multinational authorship and a registry-focused title: Homozygous familial hypercholesterolaemia from the Global HICC Registry. The lead author is Willemijn A M Schonck, and the team includes investigators from major lipid and cardiovascular centres in Europe, North America, Africa, and the Middle East. The author list and affiliations indicate contributions from Amsterdam UMC, Erasmus MC, the Perelman School of Medicine, Prince Sultan Cardiac Centre, McGill University Health Centre, and multiple other institutions. The corporate author is recorded as the Homozygous Familial Hypercholesterolaemia International Clinical Collaborators, which implies an organized international effort to pool clinical experience of this rare disorder.
The title itself signals registry-derived clinical insights into a high-risk genetic condition characterized by markedly elevated low-density lipoprotein cholesterol (LDL-C) due to inherited defects. The PubMed entry classifies the work as an observational study. That classification, together with the multi-centre affiliations, suggests the dataset represents real-world clinical practice across diverse health systems — but the excerpt does not supply the registry content needed to substantiate that interpretation.
The database record supplies clear bibliographic metadata: the article appears in European Heart Journal, with citation details (2026 Oct 26;47(40):5979-5990), DOI 10.1093/eurheartj/ehag357, and PubMed identifier (PMID 42149947). The PubMed page embeds institutional affiliations for each named author, which helps readers evaluate geographic scope and the specialty mix contributing to the registry. The entry also marks the manuscript as an observational study, and it links to the journal’s full-text options where the complete dataset and analyses should be available for review.
Those items are useful to clinicians and researchers who need to locate the primary report quickly. The presence of a DOI and the journal citation provides direct access paths for retrieval, permit citation, and enable cross-referencing to supplementary materials that are often hosted by the publisher.
The PubMed excerpt available here omits critical trial and registry specifics. The record fragment contains no abstract text, and therefore no enrolment figures, no baseline patient demographics, and no genetic testing or diagnostic criteria are provided. The excerpt does not present primary or secondary endpoints, lipid-level trajectories, cardiovascular event rates, treatment modalities used, or any statistical results. Safety data, follow-up duration, and geographic breakdown of cases are likewise absent from the posted summary.
Because the dataset and analytic details are not included in the visible PubMed excerpt, investigators reported in this summary cannot be paraphrased or interpreted beyond their bibliographic presence. Clinicians should not infer sample sizes, effect sizes, or treatment patterns from this entry alone. The registry name—Global HICC Registry—implies harmonized data collection, yet the specific methods used to harmonize case definitions, adjudicate cardiovascular events, or handle missing data were not documented in the available text.
Follow the DOI or the journal link indicated in the PubMed record to access the full article and any supplementary appendices. The PubMed listing points to full-text options on the journal platform; those documents are the only reliable source for the registry’s inclusion criteria, endpoint definitions, statistical methods, numerical outcomes, and any reported safety signals.
Clinicians and guideline committees requiring evidence for treatment decisions or comparative effectiveness assessments should obtain the full text before changing practice. Researchers who plan secondary analyses or meta-analyses must confirm case definitions, ascertainment periods, and follow-up lengths from the source article. The PubMed record does, however, establish provenance: multinational academic contributors and an observational design catalogued in a high-impact cardiology journal.
Limitations noted in this editorial summary
This rewrite is constrained to the information present in the PubMed excerpt. The excerpt did not include abstract content or numerical results; therefore no outcome data, statistical analyses, or patient-level characteristics are reported here. Readers should consult the full European Heart Journal article (DOI 10.1093/eurheartj/ehag357; PMID 42149947) for complete methods and findings. The next step for clinicians is to examine the full text for registry composition, diagnostic criteria for Homozygous familial hypercholesterolaemia, treatment exposure, and measured clinical endpoints before applying these insights in practice.